Microsphere-based immuno-therapy of HCC (C05)

基于微球的 HCC 免疫疗法 (C05)

• 批准号: 387559540
• 金额: --
• 依托单位: Klinik für Gastroenterologie, Hepatologie und Endokrinologie
• 依托单位国家: 德国
• 项目类别: CRC/Transregios
• 财政年份: 2017
• 资助国家: 德国
• 起止时间: 2016-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/387559540?language=en
• 关键词: Microsphere; based; immuno; therapy; HCC

Project C05 (Wirth; Microsphere-based immuno-therapy of HCC) aims to enhance the efficacy of tumor vaccination and improve prediction of immunotherapy response in HCC patients. The project has developed a new patented prime-boost strategy based on priming with a liposomal-encapsulated antigen followed by a costimulatory boost. In addition, they have identified novel regulators of T cell exhaustion. In the next funding period the project will test these newly identified T cell markers in HCC patient blood and will further focus on the identification of suitable HCC antigens, the functional validation in their established autochthonous HCC model and the combination of the approach with immune checkpoint inhibition and anti-angiogenic treatment.

项目C 05（沃思; HCC的基于微球的免疫疗法旨在增强肿瘤疫苗接种的功效并改善HCC患者中免疫疗法应答的预测。该项目开发了一种新的专利引发-加强策略，该策略基于用脂质体包封的抗原引发，然后进行共刺激加强。此外，他们还发现了T细胞耗竭的新调节因子。在下一个资助期内，该项目将在HCC患者血液中测试这些新发现的T细胞标志物，并将进一步专注于鉴定合适的HCC抗原，在其建立的本地HCC模型中进行功能验证，以及将该方法与免疫检查点抑制和抗血管生成治疗相结合。